ValuEngine cut shares of Vital Therapies (NASDAQ:VTL) from a buy rating to a hold rating in a research report sent to investors on Wednesday.
Several other equities research analysts have also issued reports on VTL. BidaskClub raised shares of Vital Therapies from a hold rating to a buy rating in a report on Saturday, June 30th. BTIG Research reaffirmed a hold rating on shares of Vital Therapies in a report on Monday, May 28th. William Blair raised shares of Vital Therapies from a market perform rating to an outperform rating in a report on Monday, August 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Vital Therapies in a report on Monday, August 20th. They set an overweight rating and a $18.00 price objective for the company. Seven analysts have rated the stock with a hold rating, The company has a consensus rating of Hold and a consensus price target of $12.00.
Vital Therapies stock opened at $0.35 on Wednesday. The company has a market capitalization of $19.07 million, a P/E ratio of -0.27 and a beta of 4.15. Vital Therapies has a 12-month low of $0.33 and a 12-month high of $9.75.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its holdings in Vital Therapies by 163.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 87,942 shares of the company’s stock valued at $602,000 after buying an additional 54,611 shares in the last quarter. Granahan Investment Management Inc. MA grew its holdings in Vital Therapies by 9.3% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 607,696 shares of the company’s stock valued at $4,163,000 after buying an additional 51,484 shares in the last quarter. Redmile Group LLC purchased a new stake in Vital Therapies during the 2nd quarter valued at approximately $7,502,000. BlackRock Inc. grew its holdings in Vital Therapies by 134.8% during the 2nd quarter. BlackRock Inc. now owns 2,242,025 shares of the company’s stock valued at $15,356,000 after buying an additional 1,287,310 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Vital Therapies during the 2nd quarter valued at approximately $388,000. 32.62% of the stock is owned by institutional investors and hedge funds.
Vital Therapies Company Profile
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.